• Neutropenia
• GI upset
• Prolongation of QTc interval
• Drug interactions

• CYP450 interactions ++
• Other QTc prolonging agents
• Recommend review of pt medications due to high frequency of significant interactions
• Statins - increased rhabdo
• CCBs - hypotension, AKI
• Colchicine - increased bone marrow toxicity
• Increased tacrolimus levels
• Increased phenytoin levels
• Increased INR with warfarin

Very high tissue penetration and concentration intracellularly means in vivo activity may not be predicted by in vitro testing.

May exacerbate muscle weakness in persons with myasthenia gravis. Avoid Use.